CHARITY REGISTRATION NUMBER: 1155193 Nottinghamshire Leukaemia Appeal Financial Statements 31 December 2024 Nottinghamshire Leukaemia Appeal Financial Statements Year ended 31 December 2024 Page Trustees, annual report Independent examiner's report to the trustees Statement of financial activities Statement of financial position Notes to the financial statements Nottinghamshire Leukaemia Appeal Trustees, Annual Report Year ended 31 December 2024 The trustees present their report and the unaudited financial statements ofthe charity for the year ended 31 December 2024. Reference and admlnistrative details Registered charity name Nottinghamshire Leukaemia Appeal Charity registration number 1155293 Principal office Biodiscovery Institute-room B209 University Park Nottingham NG7 2RD Trustees Mr G K Abbott Mrs M S Stoakes Dr. M J Pallis Ind8pandent examlner Mr K A Anderson Governing Document The Nottinghamshire Leukaemia Appeal also known as NLA is a charity which is an unincorporated trust governed by the Trust Deed dated 51h November 2013. Organisational Structure Trustees meet quarterly with other members of the committee. Quarterly meetings are normally held to review fund raising activities being undertaken by supporters of the NLA and to consider applications for funding of research or patient welfare. Trustees are selected on the basis of their experience and the benefits which they can bring to the charity. Other members are invited to join the committee based upon their knowledge and experience. The committee includes members who have relevant scientific medical knowledge required to assess research applications. Objectives and activities The purposes of the charity are to promote the advancement of the treatment of leukaemia and blood cancers by supporting research at Nottingham University hospitals and to promote the treatment, care and welfare of patients with leukaemia and blood cancers at Nottingham University hospitals. Nottinghamshire Leukaemia Appeal Trustees. Annual Report Year ended 31 December 2024 Achievements and performance Income Income is generated from donations and promoting sponsored events. The Trustees are very grateful to supporters of the charity in continuing to raise funds and to members of the public who have made donations. Support Nottingham University Department of Haematology has an established ethically approved bank of cells, DNA and RNA. The NLA provide £13,500 each year to make it possible to process samples from new patients, to separate and freeze their cells to make DNA and RNA and to keep alive stocks of blood cancer cell lines. This resource is essential for the success of research and has resulted in four peer- reviewed journal articles from the group in the past five years, with a further publication under re,view and others in preparation. Grundy M, Lucken K, Xing X, Simpson EL, Worker A, Bayyoomi A, Beckett AJ, Prior IA, Booth DG, Seedhouse CH. Abnormal nucleoli architecture and aggregate formation in nucleophosmin mutated acute myeloid leukaemia. Paper under review with Journal Cell Science James JR, Curd J, Ashworth JC, Abuhantash M, Grundy M, Seedhouse CH, Arkill KP, Wright AJ, Merry CLR, Thompson A. Hydrogel-Based Pre-clinical Evaluation of Repurposed FDA- Approved Drugs for AML. Int J Mol Sci. 2023',2414>'.4235 Bailey GD, Doolan L, Baskar A, Smith LC, Seedhouse CH. Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia. Scientific Reports 2020 10111 17695 Grundy M, Al-Kaisi F: Cull J, Williams C, Smith D, Seedhouse CH. A same day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3 mimetic targeting in multiple myeloma cells. EJHaem 2020 Alhuthali HM, Bradshaw TD, Lim KH, Tam KS, Seedhouse CH. The natural alkaloid Jerantinine B has activity in acute myeloid leukaemia cells through a mechanism involving c- Jun. BMC Cancer 2020 20(1) 629. Funding for the salary of Dr Martin Grundy is in place until January 2026. Dr Grundy is in charge of collection and processing patient samples and has a wealth of experience in this technically challenging area {bloodlbone marrow cells are incredibly fragile and notoriously difficult to work with to generate meaningful results). Research projects he is involved in include testing new genetic agents in leukaemia and assessing exactly what occurs in leukaemia cells as they proliferate and how this differs to normal healthy blood cells. He has also been involved in developing models for leukaemia and myeloma to best replicate what happens in a patient. In addition, Dr Grundy is working on the role of the mutated nucleophosmin protein in leukaemia and has been using special imaging equipment to study what happens in real time in leukaemia cells as they grow and divide. He has found abnormalities in leukaemia cells harbouring the mutated protein. These results have been submitted for publication in the Journal of Cell Science and the nianuscript is currently under expert review. The work is continuing to identify how we might specifically target and kill the mutant cells without affecting the normal blood cells. The NLA are also funding Dr Alexander Kondrashov for five months. Dr Kondrashov is developing novel genetic models to recreate leukaemia initiating events. This involves growing leukaemia cells from patients in special culture to allow the production and manipulations of stem cell these are the cells that start the leukaemia. The aim is to develop a novel model of early onset leukaemia. The work supported fulfils the objective of the NLA to promote the advancement of research into the treatment of leukaemia in Nottinghamshire. The quality of the funded research is evident by publication in international peer-reviewed journals (three articles published in 2018, one in 2019, three in 2020, one in 2023, one under review 2024 and several others in preparation). Nottinghamshire Leukaemia Appeal Trustees. Annual Report Year ended 31 December 2024 Research updates and outputs are regularly featured on the NLA website to ensure our supporters are aware of the research work being funded. Financial review Donations and legacies received were £3,62412023'. £4,048). Fund raising events generated net income of £35,67512023.. £42,675). Running costs were kept to a minimum at £710 (2023.. £988>. No payments (2023.. Nil) or other benefits were made to trustees and committee members. Awards and donations made were £60,548 (2.023: £123,972). Unrestricted reserves were £42,810 (2023.. £63,574). The trustees, annual ￿ port was approved on 1st September 2025 signed on behalf of the board of trustees by.. Mr G K Abbott Trustee Nottinghamshire Leukaemia Appeal Independent Examiner's Report to the Trustees of Nottinghamshire Leukaemia Appeal Year ended 31 December 2024 I report to the trustees on my examination of the financial statements of Nottinghamshire Leukaemia Appeal ('the charity,) for the year ended 31 December 2024. Responsibilities and basis of report As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 {'the Act')- I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 14515)(b) of the Act. Independent examinerfs statement I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect.. accounting records were not kept in respect of the charity as required by section 130 of the Act., or the financial statements do not accord with those ￿e0rdS., the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair, view which is not a matter considered as part of an independent examination. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be hed. Mr K A Anderson Independent Examiner % > September 2025 Nottinghamshire Leukaemia Appeal Statement of Financial Activities Year ended 31 December ?024 2024 Unrestricted funds Total funds Total funds 2023 Note Incoming Resources Income and endowments Donations and legacies Funding raising activities Investment income 3.624 35,917 2,653 3,624 35,917 2,653 4,048 44,375 1,664 Total Income 42,194 42,194 50,087 Resources Expended Costs Costs of fund-raising activities c.haritable donations and other costs 1,700 61,258 1,700 61,258 1,700 124,960 Total Outgoings 62,958 62,958 126,660 Net Ideficit) 120,7641 {20,764) 176,573) Reconclliation of funds Total funds brought forward Total funds carrled forward 63,574 63,574 140,417 42,810 63,574 The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure is derive from continuing antivities. Nottinghamshire Leukaemia Appeal Statement of Financial Position 31 December 2024 2024 2023 Note Current Assets Cash at bank and in hand 222,736 221,922 Total current assets 222, 136 221,922 Creditors: amounts falling due withln one year 10 139,737 82,366 Net Current Assets 82,999 139,556 Creditors.. amounts falling due after one year 10 40,189 75,982 Total Net Assets 42,810 63,574 Funds of the charity Unrestricted funds 42,810 63,574 Total charity funds 42,810 63,574 These financial statements were approved by the board of trustees and C4Uthorised for issue on and are signed on behalf of the bo8rd of trustees by.. Mr G K Abbott Trustee Nottinghamshire Leukaemia Appeal Notes to the Financial Statements (continued) Year ended 31 December 2024 General information The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is Biodiscovery Institute-room B209 University Park ,Nottingham, NG7 2RD. Statement of compliance These financial statements have been prepared in compliance with FP.S 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland,, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland {FRS 1021 (Charities SORP (FRS 102)) and the Charities Act 2011. Accountlng policies Basis of preparatlon The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure. The financial statements are prepared in sterling, which is the functional currency of the entity. Golng concern There are no material uncertainties about the charity's ability to continue. Judgements and key sources of estimation uncertainty The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Incomlng resources All incoming resources are included in the statement of financial activities when entitlement has passed to the charity,. it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of inc.ome'. income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably. legacy income is recognised when receipt is probable and entitlement is established. Resources expended Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement offinancial activities to which it relates.. expenditure on raising funds includes the costs of all fundraising activities, events, non- charitable trading activities, and the sale of donated goods. expenditure on charitable activities includes all costs incurred by a charity in undertaking Nottinghamshire Leukaemia Appeal Notes to the Financial Statements (continued) Year ended 31 December 2024 activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities. other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities. All costs are allocated to expenditure categories reflecting the use of the resour￿. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned be￿een the activities they contribute to on a reasonable, justifiable and consistent basis. Donations and legacies Total Funds Total Funds 2024 2023 Donations Donations and Legacies 3,624 4,048 Fund raising activities Total Funds Total Funds 2024 2023 Fundraising activities 35,917 44,375 Investment Income Total Funds Total Funds 2024 2023 Bank interest receivable 2,653 1,664 Costs of fundraising activities Total Funds Total Funds 2024 2023 Fund raising costs 1,700 1,700 Expenditure on charitable activities Total Funds Total Funds 2024 2023 Charity donations and support Administration and support costs 60,548 710 113,972 988 61,258 114,960 Nottir.ghamshire Leukaemia Appeal Notes to the Financial Statemeiits {continuedJ Year ended 31 December 2024 Trustee reniuneration and expenses No rp.mun-ration or other benefits were received by Ihe trustees. 10. Creditors Creditors include committed support on 3 1 December 2024 of £179,92812023: £156,648) ofwhich £40,189 (2023.. £75,982) is due after mure thdn one year.